Head to head
Stepan vs Linde
Side-by-side on the measures that matter, with a plain-English read. Full detail: SCL · LIN
SCL
Stepan
61.32-1.72%
1-year price shape — +33% over the period
Quant Rating B · 71/100
vs
LIN
Linde
483.98-1.22%
1-year price shape — +4% over the period
Quant Rating D · 45/100
1-year performance, rebased to 100
Linde edges it on the scoreable measures. Linde earns the most per share.
| SCL | LIN | |
|---|---|---|
| Snapshot | ||
| Sector | Specialty Chemicals | Specialty Chemicals |
| Last price | 61.32 | 483.98 |
| Change today | -1.72% | -1.22% |
| 1-year return | +32.5% | +4.3% |
| Market cap | $1.39B | $223.11B |
| 52-week range | 40.57 – 66.55 | 384.00 – 546.40 |
| Valuation | ||
| P/E (TTM) | -511.00 | 31.22 |
| P/E percentile, own 5-yr range | 3rd | 8th |
| P/B | 1.15 | 5.71 |
| Dividend yield | 2.56% | 1.28% |
| Profitability & growth | ||
| EPS (TTM) | 2.05 | 14.61 |
| Net profit (TTM) | $46.60M | $6.73B |
| Revenue (TTM) | $2.43B | $35.45B |
| Revenue growth (YoY) | +15.0% | +9.3% |
| Gross margin | 11.8% | 48.3% |
| Operating margin | 3.3% | 27.1% |
| Net margin | -0.1% | 20.4% |
| Free cash flow (TTM) | $36.58M | $4.98B |
| Ownership & sentiment | ||
| Institutional ownership | 89.1% | 88.0% |
| Insider activity (12mo) | 26 buy / 10 sell | 33 buy / 13 sell |
| Short interest (% of float) | 2.9% | 1.3% |
| Analyst consensus | 100% buy (1) | 87% buy / 13% hold (15) |
| Analyst price target | $85 (+39%) | $557 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | B (71) | D (45) |
| Company | ||
| Employees | 2,328 | 65,177 |
| Founded | 1932 | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.